Evidence map›Paper›PMID 27655679›Full record

ArticleOncotarget2016

Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.

Elizabeth Shurell, Maria E Vergara-Lluri, Yunfeng Li, Joseph G Crompton, Arun Singh, Nicholas Bernthal, Hong Wu, Fritz C Eilber, Sarah M Dry

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. NY-ESO-1 as a diagnostic and prognostic marker for myxoid liposarcoma.American journal of translational research · 2022
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters.Current treatment options in oncology · 2018
    Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Elizabeth ShurellDivision of Surgical Oncology, University of California, Los Angeles, CA 90095, USA.
Maria E Vergara-LluriDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095, USA.
Yunfeng LiDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095, USA.
Joseph G CromptonDivision of Surgical Oncology, University of California, Los Angeles, CA 90095, USA.
Arun SinghDepartment of Hematology/Oncology, University of California, Los Angeles, CA 90095, USA.
Nicholas BernthalDepartment of Orthopaedic Surgery, University of California, Los Angeles, CA 90095, USA.
Hong WuDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095, USA.
Fritz C EilberDivision of Surgical Oncology, University of California, Los Angeles, CA 90095, USA.
Sarah M DryDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095, USA.
University of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
TUMOR CELL SURFACES AND CHROMOSOMEST32CA009056 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gay M Crooks, David A. Nathanson · 1985 to 2026
$10.5M
NCI NIH HHS P30 CA016042NCI NIH HHS T32 CA009056
6 · The paper itself

Abstract

backgroundImmunotherapy targeting cancer-testis antigen NY-ESO-1 shows promise for tumors with poor response to chemoradiation. Malignant peripheral nerve sheath tumors (MPNSTs) and liposarcomas (LPS) are chemoresistant and have few effective treatment options. Materials Methods: Using a comprehensive tissue microarray (TMA) of both benign and malignant tumors in primary, recurrent, and metastatic samples, we examined NY-ESO-1 expression in peripheral nerve sheath tumor (PNST) and adipocytic tumors. The PNST TMA included 42 MPNSTs (spontaneous n = 26, NF1-associated n = 16), 35 neurofibromas (spontaneous n = 22, NF-1 associated n = 13), 11 schwannomas, and 18 normal nerves. The LPS TMA included 48 well-differentiated/dedifferentiated (WD/DD) LPS, 13 myxoid/round cell LPS, 3 pleomorphic LPS, 8 lipomas, 1 myelolipoma, and 3 normal adipocytic tissue samples. Stained in triplicate, NY-ESO-1 intensity and density were scored.

resultsNY-ESO-1 expression was exclusive to malignant tumors. 100% of myxoid/round cell LPS demonstrated NY-ESO-1 expression, while only 6% of WD/DD LPS showed protein expression, one of which was WD LPS. Of MPNST, 4/26 (15%) spontaneous and 2/16 (12%) NF1-associated MPNSTs demonstrated NY-ESO-1 expression. Strong NY-ESO-1 expression was observed in myxoid/round cell and dedifferentiated LPS, and MPNST in primary, neoadjuvant, and metastatic settings.

conclusionsWe found higher prevalence of NY-ESO-1 expression in MPNSTs than previously reported, highlighting a subset of MPNST patients who may benefit from immunotherapy. This study expands our understanding of NY-ESO-1 in WD/DD LPS and is the first demonstration of staining in a WD LPS and metastatic/recurrent myxoid/round cell LPS. These results suggest immunotherapy targeting NY-ESO-1 may benefit patients with aggressive tumors resistant to conventional therapy.

Indexed as

Tissue Array AnalysisAdipogenesisAdipose TissueAntigens, NeoplasmBiomarkersHumansImmunohistochemistryImmunotherapyLiposarcomaMembrane ProteinsNeoplasm MetastasisNeoplasm Recurrence, LocalNerve Sheath NeoplasmsNerve TissueNeurogenesisAntigens, NeoplasmBiomarkersCTAG1B protein, humanMembrane ProteinsimmunotherapyliposarcomaMPNSTNY-ESO-1sarcoma

Identifiers

PMID27655679
PMCPMC5341949
OpenAlexW2540409119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.